Daiichi could be rewarded for persisting with Vanflyta

Daiichi could be rewarded for persisting with Vanflyta

Source: 
EP Vantage
snippet: 

Persistence sometimes pays off in drug development, as Daiichi Sankyo might soon find out. Two years after the FDA kicked out a filing for Vanflyta in relapsed/refractory AML, the drug’s front-line AML study, Quantum-First, has read out positively for overall survival.